Cardiac marker POCT
Acute cardiovascular disease such as acute myocardial infarction (AMI) is the leading cause of death in most cardiovascular diseases. AMl, which is a real threat to the safety of patients, accounts for only 1/4 of the total number of patients with chest pain. Patients with chest pain who are sent to the emergency room often undergo extensive diagnostic tests and risk stratification for the diagnosis of acute coronary syndromes and the possibility of determining future cardiac events. RADIOMETER POCT experts believe that to ensure that the right POCT solution is chosen, health care professionals first need to evaluate the clinical, scientific, and practical aspects involved. Other patients with chest pain need no further treatment in the hospital. If it is not possible to diagnose patients with chest pain in a short period of time without lethal AMI, then those who are not AMI should not only be astonished at their own fingertips, but also take extra large doses of medicine every day Fee and hospital fee. Not only that, some patients with AMI because of the diagnosis is not timely treatment and delay the delay or even death. Therefore, rapid clinical diagnosis is important for the patient's rescue and treatment and for controlling the progression of the disease. With the continuous development of testing technology, serum myocardial markers have gained more and more attention in clinical practice in recent years. Cardiac protein markers, such as cardiac troponin I (cTnI), are highly specific and sensitive to myocardial injury and have become the diagnostic markers for the clinical diagnosis of myocardial injury, especially for the clinical diagnosis of acute myocardial infarction .
Myoglobin (MyO) is the most important indicator of early diagnosis of myocardial infarction (AMI). Creatine kinase isoenzyme (CK-MB) is the clinician's most reliable myocardial marker for diagnosing AMI. Cardiac troponin I / T is Cardiac injury test of gold standard, B natriuretic peptide (BNP) is a new diagnostic marker of congestive heart failure, can help diagnose congestive heart failure, to determine the severity and prognosis of the disease, and guide the treatment. At present, the above indexes can all be determined by POCT method, which is of great significance for early diagnosis of myocardial injury diseases, especially myocardial infarction, and timely and effective treatment measures.
POCT, a cardiac marker, can be used to promptly treat patients with AMI in need of treatment promptly and correctly so as to shorten the time for medical treatment. On the other hand, POCT can reduce the medical cost of the society and reduce the expenses for those patients who do not need further treatment. The necessary medical occupancy allows the hospital to treat more patients. Cardiac markers have rapidly developed in recent decades and new markers are emerging. In addition to having a certain sensitivity and specificity, ideal markers need to provide valuable information to help physicians screen, diagnose, stratify risk and predict prognosis. As mentioned above, BNP, Cys-C and interleukin, CRP and cTn, etc. in turn respond to different stages of the cardiovascular event chain and can be used for disease judgment. In addition, the combination of multiple biomarkers may be an important means of future cardiovascular risk assessment, which can improve the efficiency of diagnosis and treatment of cardiovascular diseases and the accuracy of prognostic judgment.
The company specializes in providing POCT test kit production and sales, customers are welcome to consult the procurement.